Gladius Capital Management LP Ironwood Pharmaceuticals Inc Transaction History

Gladius Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Dec 18, 2023	BUY	$10.37 - $12.56 $31,856 - $38,584	3,072 New	3,072 $32,000
Q1 2023 May 09, 2023	SELL	$10.37 - $12.56 $1,078 - $1,306	-104 Reduced 3.27%	3,072 $33,000
Q4 2022 Dec 18, 2023	BUY	$9.9 - $12.43 $31,442 - $39,477	3,176 New	3,176 $39,000
Q4 2022 Feb 02, 2023	BUY	$9.9 - $12.43 $31,442 - $39,477	3,176 New	3,176 $40,000
Q2 2022 Aug 10, 2022	BUY	$11.05 - $12.72 $52,609 - $60,559	4,761 New	4,761 $55,000

235

162M

11.2M

9.1K

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $561M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

Get notified when there are updates to the investment portfolio of Gladius Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Gladius Capital Management LP with notifications on news.